Abnormal metabolic brain networks in Parkinson's disease. From blackboard to bedside

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 160-176

  Tang, Chris C ^a   Eidelberg, David ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Brain networks; Differential diagnosis; Glucose metabolism; Parkinson's disease

Indexed keywords

AKINESIA; BOOK; BRAIN; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENE THERAPY; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; SUBTHALAMIC NUCLEUS; TREMOR; ANIMAL; BRAIN LEVEL; COGNITION; METABOLISM; MOVEMENT (PHYSIOLOGY); PATHOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMALS; BRAIN CHEMISTRY; COGNITION; DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DOPAMINE AGENTS; GENE THERAPY; HUMANS; MOVEMENT; PARKINSON DISEASE;

EID: 77957244311     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84008-7     Document Type: Chapter

References (66)

1. Aarsland D., Zaccai J., Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 2005, 20(10):1255-1263.
2. Albin R.L., Koeppe R.A., Chervin R.D., Consens F.B., Wernette K., Frey K.A., et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55(9):1410-1412.
3. Antonini A., Moeller J.R., Nakamura T., Spetsieris P., Dhawan V., Eidelberg D. The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998, 51(3):803-810.
4. Argyelan M., Carbon M., Ghilardi M.F., Feigin A., Mattis P., Tang C., et al. Dopaminergic suppression of brain deactivation responses during sequence learning. Journal of Neuroscience 2008, 28(42):10687-10695.
5. Asanuma K., Tang C., Ma Y., Dhawan V., Mattis P., Edwards C., et al. Network modulation in the treatment of Parkinson's disease. Brain 2006, 129(Pt 10):2667-2678.
6. Benabid A.L., Chabardes S., Mitrofanis J., Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurology 2009, 8(1):67-81.
7. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of Neurological Science 1973, 20(4):415-455.
8. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends in Neuroscience 2003, 26(4):215-221.
9. Braak H., Del Tredici K., Rub U., De Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003, 24(2):197-211.
10. Braak H., Rub U., Jansen Steur E.N., Del Tredici K., De Vos R.A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005, 64(8):1404-1410.
11. Buhmann C., Glauche V., Sturenburg H.J., Oechsner M., Weiller C., Buchel C. Pharmacologically modulated fMRI - cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003, 126(Pt 2):451-461.
12. Doepp F., Plotkin M., Siegel L., Kivi A., Gruber D., Lobsien E., et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Movement Disorder 2008, 23(3):405-410.
13. Eberling J.L., Jagust W.J., Christine C.W., Starr P., Larson P., Bankiewicz K.S., et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70(21):1980-1983.
14. Eckert T., Tang C., Ma Y., Brown N., Lin T., Frucht S., et al. Abnormal metabolic networks in atypical parkinsonism. Movement Disorder 2008, 23(5):727-733.
15. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends in Neuroscience 2009, 32(10):548-557.
16. Eidelberg D., Moeller J.R., Dhawan V., Sidtis J.J., Ginos J.Z., Strother S.C., et al. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Movement Disorder 1990, 5(3):203-213.
17. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., et al. The metabolic topography of parkinsonism. Journal of Cerebral Blood Flow and Metabolism 1994, 14(5):783-801.
18. Eidelberg D., Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. Journal of Nuclear Medicine 1995, 36(3):378-383.
19. Eidelberg D., Moeller J.R., Kazumata K., Antonini A., Sterio D., Dhawan V., et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997, 120(Pt 8):1315-1324.
20. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F.J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000, 123(Pt 6):1155-1160.
21. Emborg M.E., Carbon M., Holden J.E., During M.J., Ma Y., Tang C., et al. Subthalamic glutamic acid decarboxylase gene therapy: Changes in motor function and cortical metabolism. Journal of Cerebral Blood Flow and Metabolism 2007, 27(3):501-509.
22. Emre M. What causes mental dysfunction in Parkinson's disease?. Movement Disorder 2003, 18(Suppl 6):S63-S71.
23. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. New England Journal of Medicine 2004, 351(24):2498-2508.
24. Feigin A., Antonini A., Fukuda M., De Notaris R., Benti R., Pezzoli G., et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Movement Disorder 2002, 17(6):1265-1270.
25. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001, 57(11):2083-2088.
26. Feigin A., Kaplitt M.G., Tang C., Lin T., Mattis P., Dhawan V., et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(49):19559-19564.
27. Feigin A., Tang C., Ma Y., Mattis P., Zgaljardic D., Guttman M., et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007, 130(Pt 11):2858-2867.
28. Fukuda M., Mentis M.J., Ma Y., Dhawan V., Antonini A., Lang A.E., et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. Brain 2001, 124(Pt 8):1601-1609.
29. Habeck C., Foster N.L., Perneczky R., Kurz A., Alexopoulos P., Koeppe R.A., et al. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage 2008, 40(4):1503-1515.
30. Habeck C., Stern Y. Neural network approaches and their reproducibility in the study of verbal working memory and Alzheimer's disease. Clinical Neuroscience Research 2007, 6(6):381-390.
31. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. Journal of Neuroscience 2008, 28(16):4201-4209.
32. Hirano S., Eckert T., Flanagan T., Eidelberg D. Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease. Movement Disorder 2009, 24(Suppl 2):S725-S731.
33. Huang C., Mattis P., Tang C., Perrine K., Carbon M., Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007, 34(2):714-723.
34. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70(16 Pt 2):1470-1477.
35. Huang C., Tang C., Feigin A., Lesser M., Ma Y., Pourfar M., et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130(Pt 7):1834-1846.
36. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55(3):181-184.
37. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study. 1992. Neurology 2001, 57(10 Suppl 3):S34-S38.
38. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125(Pt 4):861-870.
39. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry 1992, 55(3):181-184.
40. Hughes A.J., Daniel S.E., Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001, 57(8):1497-1499.
41. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54(10):1916-1921.
42. Isaias I.U., Marotta G., Hirano S., Canesi M., Benti R., Righini A., et al. Imaging essential tremor. Movement Disorder 2010, 25(6):679-686.
43. Jellinger K.A., Seppi K., Wenning G.K., Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. Journal of Neural Transmission 2002, 109(3):329-339.
44. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 2007, 369(9579):2097-2105.
45. Lee B., Lee H., Nam Y.R., Oh J.H., Cho Y.H., Chang J.W. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Therapy 2005, 12(15):1215-1222.
46. Lin T.P., Carbon M., Tang C., Mogilner A.Y., Sterio D., Beric A., et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 2008, 131(Pt 5):1373-1380.
47. Louis E.D., Tang M.X., Cote L., Alfaro B., Mejia H., Marder K. Progression of parkinsonian signs in Parkinson disease. Archives of Neurology 1999, 56(3):334-337.
48. Lozza C., Baron J.C., Eidelberg D., Mentis M.J., Carbon M., Marie R.M. Executive processes in Parkinson's disease: FDG-PET and network analysis. Human Brain Mapping 2004, 22(3):236-245.
49. Luo J., Kaplitt M.G., Fitzsimons H.L., Zuzga D.S., Liu Y., Oshinsky M.L., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002, 298(5592):425-429.
50. Ma Y., Tang C., Spetsieris P.G., Dhawan V., Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. Journal of Cerebral Blood Flow and Metabolism 2007, 27(3):597-605.
51. Moeller J.R., Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 1997, 120(Pt 12):2197-2206.
52. Osaki Y., Ben-Shlomo Y., Lees A.J., Daniel S.E., Colosimo C., Wenning G., et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disorder 2004, 19(2):181-189.
53. Osaki Y., Wenning G.K., Daniel S.E., Hughes A., Lees A.J., Mathias C.J., et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?. Neurology 2002, 59(10):1486-1491.
54. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287(13):1653-1661. Parkinson Study Group, P.S.
55. Poston K.L., Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiology of Disease 2009, 35(2):141-147.
56. Pourfar M., Tang C., Lin T., Dhawan V., Kaplitt M.G., Eidelberg D. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. Journal of Neurosurgery 2009, 110(6):1278-1282.
57. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry 2000, 69(3):308-312.
58. Shih L.C., Tarsy D. Deep brain stimulation for the treatment of atypical parkinsonism. Movement Disorder 2007, 22(15):2149-2155.
59. Smith A.D., Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Experimental Neurology 2003, 184(1):31-39.
60. Spetsieris P.G., Ma Y., Dhawan V., Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 2009, 45(4):1241-1252.
61. Tang C.C., Poston K.L., Dhawan V., Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. Journal of Neuroscience 2010, 30(3):1049-1056.
62. Tang C.C., Poston K.L., Eckert T., Feigin A., Frucht S., Gudesblatt M., et al. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurology 2010, 9(2):149-158.
63. Trost M., Su P.C., Barnes A., Su S.L., Yen R.F., Tseng H.M., et al. Evolving metabolic changes during the first postoperative year after subthalamotomy. Journal of Neurosurgery 2003, 99(5):872-878.
64. Trost M., Su S., Su P., Yen R.F., Tseng H.M., Barnes A., et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006, 31(1):301-307.
65. Vlaar A.M., Van Kroonenburgh M.J., Kessels A.G., Weber W.E. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurology 2007, 7(27).
66. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology 2003, 54(1):93-101.